Benchmark lowered the firm's price target on Harvard Bioscience to 60c from $2 and keeps a Speculative Buy rating on the shares. The timing of recovery continues to be difficult to peg, says the analyst, who is lowering the firm's 2026 revenue estimate to $89.2M from $95.6M.
